The consent form lists the known adverse events for a reason: they come from preclinical data and any prior human exposure to the compound. Reading that list tells you what to watch for. It doesn't tell you how likely any individual event is, or what grade of severity is expected. That's where the formal system comes in.
The grading system
Clinical trials use the Common Terminology Criteria for Adverse Events (CTCAE) — a standardized scale from 1 to 5:
Grade 1 — Mild. Doesn't interfere with your daily activity. Nausea that passes after a few hours, a mild headache, temporary fatigue. Usually managed with reassurance or minor symptomatic treatment.
Grade 2 — Moderate. Interferes with some daily activities but doesn't prevent them entirely. Persistent nausea requiring medication, noticeable fatigue that limits exertion. Often triggers a dose adjustment discussion.
Grade 3 — Severe. Disabling. Prevents normal activity and may require hospitalization or IV treatment. This grade typically triggers a mandatory dose hold and a protocol-specified response.
Grade 4 — Life-threatening. Requires urgent intervention. Automatically triggers suspension of treatment pending safety review.
Grade 5 — Death related to the adverse event. Results in immediate regulatory reporting, data safety monitoring board review, and often a trial pause or stop.
Most participants in well-designed trials experience Grade 1-2 events. The protocol specifies in advance what happens at each grade — dose reduction rules, hold periods, stopping criteria. You won't need to know the CTCAE system yourself, but understanding it helps you interpret what the team tells you when they grade your symptoms.
What to report and when
Report everything. Not because every symptom is significant, but because the team needs the full picture to distinguish signal from noise. What seems minor to you may be clinically important when combined with other participants' data.
Contact the study team immediately — not at your next scheduled visit — if you experience: chest pain, difficulty breathing, a new fever, significant swelling, severe abdominal pain, any sudden neurological symptom (confusion, vision change, weakness), or anything that feels acutely wrong. These are Grade 3+ signals by definition.
For milder symptoms, record them in your study diary (if you have one) and bring them up at your next visit. Don't wait for them to resolve before mentioning them.
Managing expected side effects
The consent form usually includes a section on symptom management — what the team recommends for common side effects like nausea, fatigue, or injection site reactions. Follow it. Don't self-medicate with anything not discussed with the study team, because some OTC medications interact with investigational compounds or confound the data.
Ask specifically: which over-the-counter medications are safe for me to take during this trial? Get a list before you need it. The time to ask is before you're feeling unwell at 11pm wondering whether ibuprofen is going to cause a problem.
When your body tells you something is wrong
Trust yourself. The grading system and the protocol are important, but your subjective experience matters. If something feels significantly wrong — beyond what seems reasonable given what you were told to expect — escalate. Call the 24-hour safety line that should appear in your participant documentation. If you don't have it, ask for it at your next visit and save it before you need it.
No study team should ever discourage you from reporting symptoms. If anyone suggests you're overreacting, that's not an acceptable response. Push back.